Strain sUrveillance during Chemotherapy for improving Cardiovascular OUtcomes
- Conditions
- Cancer therapeutics-related cardiac dysfunction
- Registration Number
- JPRN-UMIN000019417
- Lead Sponsor
- Menzies Institute for Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 320
Not provided
1. Unable to provide written informed consent to participate in this study 2. Participating in another clinical research trial where randomized treatment would be unacceptable 3. Valvular stenosis or regurgitation of >moderate severity 4. History of previous heart failure (baseline NYHA >2) 5. Systolic BP <110mmHg 6. Pulse <60/minute 7. Inability to acquire interpretable images (identified from baseline echo) 8. Contraindications/Intolerance to beta blockers or ACE inhibitors 9. Existing therapy with both beta blockers and ACE inhibitors 10. Oncologic (or other) life expectancy <12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary study end-point is change in 3D ejection fraction from baseline to up to three years, as determined by a blinded core laboratory and analyzed on an intention-to-treat basis according to random study group allocation.
- Secondary Outcome Measures
Name Time Method